Antibacterial effects of leukocyte and platelet-rich fibrin against Escherichia coli and Enterococcus faecalis

Year 2021, Volume: 5 Issue: 2, 132 - 137, 30.08.2021

Mehtap Bilgin Çetin , Yasemin Sezgin , Ebru Evren , Prof. Dr. Şule Bulut

https://doi.org/10.30565/medalanya.850173

Abstract

Aim: The main goal of this research was to explore the in-vitro antibacterial characteristics of leukocyte and platelet-rich fibrin (L-PRF) against Escherichia coli (E. Coli) and Enterococcus faecalis (E. Faecalis).

Materials and methods: The study was conducted on 21 patients (10 females, 11 males, age range 21-32 years). L-PRF was prepared from the participants’ own blood. Antibacterial activity of L-PRF against E. coli and E. faecalis ATCC standard strains was analyzed using the Kirby Bauer disk diffusion method.

Results: The inhibition zones with PRF had not been detected even though the results obtained using control discs were in accordance with the expectations.

Conclusion: L-PRF demonstrated no inhibition zone against E. coli and E. faecalis.

Keywords

Antibacterial, Escherichia Coli, Enterococcus Faecalis, Leukocyte and Platelet-Rich Fibrin, postoperative infection.

Supporting Institution

Başkent Üniversitesi Diş Hekimliği Fakültesi

Project Number

D-KA 14/21

Thanks

Authors, thank to all individuals who participated in the study.

Lökosit ve Trombositten Zengin Fibrinin Escherichia Coli’ye ve Enterococcus Faecalis'e Karşı Antibakteriyel Etkileri

Abstract

Amaç: Bu çalışmanın amacı, lökosit ve trombositten zengin fibrinin (TZF) Escherichia coli’ye (E. Coli) ve Enterococcus faecalis'e (E. Faecalis) karşı in vitro antibakteriyel etkilerini araştırmaktır.

Gereç ve yöntemler: Çalışma 21 hasta (10 kadın, 11 erkek, yaş aralığı 21-32 yaş) üzerinde yürütülmüştür. Katılımcılardan elde edilen kan örnekleri kullanılarak TZF hazırlanmıştır. TZF'nin E. coli ve E. faecalis ATCC standart suşlarına antibakteriyel aktivitesi Kirby Bauer disk difüzyon yöntemi kullanılarak test edilmiştir.

Bulgular: Beklenen sonuçlar kontrol diski ile elde edilmesine rağmen, TZF’nin değerlendirilen bakterilere karşı inhibisyon zonu göstermediği tespit edilmiştir.

Sonuç: TZF, E.coli’ye ve E. faecalis’e karşı inhibisyon bölgesi göstermemiştir.

Keywords

Antibakteriyel,, Escherichia Coli,, Enterococcus Faecalis, lökosit ve trombositten zengin fibrin, postoperatif enfeksiyon

Project Number

D-KA 14/21

References

• 1. Moraschini V, Barboza Edos S. Use of Platelet-Rich Fibrin Membrane in the Treatment of Gingival Recession: A Systematic Review and Meta-Analysis. J Periodontol. 2016;87:281-90. PMID: 26561997
• 2. Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, et al., Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101:e37-44. PMID: 16504849
• 3. Dohan Ehrenfest DM, Del Corso M, Diss A, Mouhyi J, Charrier JB. Three-dimensional architecture and cell composition of a Choukroun's platelet-rich fibrin clot and membrane. J Periodontol. 2010;81:546-55. PMID: 20373539
• 4. Dohan Ehrenfest DM, de Peppo GM, Doglioli P, Sammartino G. Slow release of growth factors and thrombospondin-1 in Choukroun's platelet-rich fibrin (PRF): a gold standard to achieve for all surgical platelet concentrates technologies. Growth Factors. 2009;27:63-9. PMID: 19089687
• 5. Panda S, Doraiswamy J, Malaiappan S, Varghese SS, Del Fabbro M. Additive effect of autologous platelet concentrates in treatment of intrabony defects: a systematic review and meta-analysis. J Investig Clin Dent. 2016;7:13-26. PMID: 25048153
• 6. Li Q, Pan S, Dangaria SJ, Gopinathan G, Kolokythas A, Chu S, et al., Platelet-rich fibrin promotes periodontal regeneration and enhances alveolar bone augmentation. Biomed Res Int. 2013;2013:638043. PMID: 23586051
• 7. Su NY, Yang LC, Chang YC. Platelet-rich fibrin is the first-line treatment option for periodontal regeneration. J Dent Sci. 2017;12:203-4. PMID:30895051
• 8. Dohan Ehrenfest DM, Andia I, Zumstein MA, Zhang CQ, Pinto NR, Bielecki T. Classification of platelet concentrates (Platelet-Rich Plasma-PRP, Platelet-Rich Fibrin-PRF) for topical and infiltrative use in orthopedic and sports medicine: current consensus, clinical implications and perspectives. Muscles Ligaments Tendons J. 2014;4:3-9. PMID: 24932440
• 9. Fabbro MD, Bortolin M, Taschieri S, Ceci C, Weinstein RL. Antimicrobial properties of platelet-rich preparations. A systematic review of the current pre-clinical evidence. Platelets. 2016;27:276-85. PMID: 26763769
• 10. Drago L, Bortolin M, Vassena C, Taschieri S, Del Fabbro M. Antimicrobial activity of pure platelet-rich plasma against microorganisms isolated from oral cavity. BMC Microbiol. 2013;13:47. PMID: 23442413
• 11. Yang LC, Hu SW, Yan M, Yang JJ, Tsou SH, Lin YY. Antimicrobial Activity of Platelet-Rich Plasma and Other Plasma Preparations Against Periodontal Pathogens. J Periodontol. 2015;86:310-8. PMID:25345340 12. Aggour RL, Gamil L. Antimicrobial Effects of Platelet-rich Plasma against Selected Oral and Periodontal Pathogens. Pol J Microbiol. 2017;66:31-7. PMID: 29359696
• 13. Badade PS, Mahale SA, Panjwani AA, Vaidya PD, Warang AD. Antimicrobial effect of platelet-rich plasma and platelet-rich fibrin. Indian J Dent Res. 2016;27:300-4. PMID: 27411660
• 14. Edelblute CM, Donate AL, Hargrave BY, Heller LC. Human platelet gel supernatant inactivates opportunistic wound pathogens on skin. Platelets. 2015;36:1499–1506. PMID: 24433255
• 15. Burnouf T,Chou ML, Wu YW, Su CY, Lee LW. Antimicrobial activity of platelet (PLT)-poorplasma, PLT-richplasma, PLT gel, and solvent/detergent-treated PLT lysate biomaterials against wound bacteria. Transfusion. 2013;53:138–46. PMID: 22563709
• 16. Drago L, Bortolin M, Vassena C, Romanò CL, Taschieri S, Del Fabbro M. Plasma components and platelet activation are essential for the antimicrobial properties of autologous platelet-rich plasma: an in vitro study. PLoS One. 2014;9:e107813. PMID: 25232963
• 17. Castro AB, Herrero ER, Slomka V, Pinto N, Teughels W, Quirynen M. Antimicrobial capacity of leucocyte-and platelet rich fibrin against periodontal pathogens. Sci Rep. 2019;9:8188. PMID: 31160643
• 18. Yalçın Ü. Comparison of efficacy of platelet-rich plasma and extracorporeal shock-wave therapy on pain and functional capacity in patients with Plantar Fasciitis. Acta Med Alanya. 2020;4(1):3-9. DOI:10.30565/medalanya.566188
• 19. Giacometti A, Cirioni O, Schimizzi AM, Del Prete MS, Barchiesi F, D'Errico MM, et al., Epidemiology and microbiology of surgical wound infections. J Clin Microbiol. 2000;38:918-22. PMID: 10655417
• 20. Zalavras CG, Patzakis MJ, Holtom P. Local antibiotic therapy in the treatment of open fractures and osteomyelitis. Clin Orthop Relat Res. 2004;86-93. PMID: 15552142
• 21. Mariani E, Filardo G, Canella V, Berlingeri A, Bielli A, Cattini L, et al., Platelet-rich plasma affects bacterial growth in vitro. Cytotherapy. 2014;16:1294–304. PMID:25108654
• 22. Bielecki TM, Gazdzik TS, Arendt J, Szczepanski T, Krol W, Wielkoszynski T. Antibacterial effect of autologous platelet gel enriched with growth factors and other active substances: an in vitro study. J Bone Joint Surg Br. 2007;89:417-20. PMID: 17356164
• 23. Li H, Hamza T, Tidwell JE, Clovis N, Li B. Unique antimicrobial effects of platelet-rich plasma and its efficacy as a prophylaxis to prevent implant-associated spinal infection. Adv Healthc Mater. 2013;2:1277-84. PMID: 23447088
• 24. Anitua E, Sanchez M, Orive G, Andia I. The potential impact of the preparation rich in growth factors (PRGF) in different medical fields. Biomaterials. 2007;28:4551-60. PMID: 17659771